Multicenter phase II trial of S-1 in patients with cytokine-refractory metastatic renal cell carcinoma

Journal of Clinical Oncology

Volumn 28, Issue 34, 2010, Pages 5022-5029

  Naito, Seiji ^a   Eto, Masatoshi ^a   Shinohara, Nobuo ^a   Tomita, Yoshihiko ^a   Fujisawa, Masato ^a   Namiki, Mikio ^a   Nishikido, Masaharu ^a   Usami, Michiyuki ^a   Tsukamoto, Taiji ^a   Akaza, Hideyuki ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ALPHA INTERFERON; FLUOROURACIL; INTERLEUKIN 2; MESSENGER RNA; SORAFENIB; SUNITINIB; THYMIDYLATE SYNTHASE;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG SAFETY; FATIGUE; FEMALE; HEMATOLOGIC DISEASE; HUMAN; HYPERGLYCEMIA; HYPOALBUMINEMIA; JAPANESE; KIDNEY CARCINOMA; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOPENIA; MALE; METASTASIS; MULTICENTER STUDY; NAUSEA; NEPHRECTOMY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PIGMENT DISORDER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SIDE EFFECT; STOMATITIS; TASTE; THROMBOCYTOPENIA; TREATMENT RESPONSE;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, RENAL CELL; DIHYDROURACIL DEHYDROGENASE (NADP); DISEASE-FREE SURVIVAL; DRUG COMBINATIONS; FEMALE; GENE EXPRESSION; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OROTATE PHOSPHORIBOSYLTRANSFERASE; OXONIC ACID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SALVAGE THERAPY; TEGAFUR; THYMIDINE KINASE; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME;

EID: 79951888205     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.29.1203     Document Type: Article

References (42)

1. Motzer RJ, Russo P: Systemic therapy for renal cell carcinoma. J Urol 163:408-417, 2000 (Pubitemid 30060482)
2. Escudier B, Pluzanska A, Koralewski P, et al: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 370:2103-2111, 2007 (Pubitemid 350296300)
3. Hudes G, Carducci M, Tomczak P, et al: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271-2281, 2007 (Pubitemid 46849157)
4. Escudier B, Eisen T, Stadler WM, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134, 2007 (Pubitemid 46089673)
5. Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124, 2007 (Pubitemid 46089672)
6. Motzer RJ, Escudier B, Oudard S, et al: Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449-456, 2008
7. Shirasaka T, Shimamato Y, Ohshimo H, et al: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7:548-557, 1996 (Pubitemid 26276346)
8. Tatsumi K, Fukushima M, Shirasaka T, et al: Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res 78:748-755, 1987 (Pubitemid 17132408)
9. Shirasaka T, Shimamoto Y, Fukushima M: Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 53:4004-4009, 1993 (Pubitemid 23267702)
10. Naito S, Tsukamoto T, Usami M, et al: An early phase II trial of S-1 in Japanese patients with cytokine-refractory metastatic renal cell carcinoma. Cancer Chemother Pharmacol 78:323-328, 2010
11. Ichikawa W, Takahashi T, Suto K, et al: Simple combinations of 5-FU pathway genes predict the outcome of metastatic gastric cancer patients treated by S-1. Int J Cancer 119:1927-1933, 2006
12. Fukushima M, Nomura H, Murakami Y, et al: Estimation of pathways of 5-fluorouracil anabolism in human cancer cells in vitro and in vivo [in Japanese]. Gan To Kagaku Ryoho 23:721-731, 1996 (Pubitemid 26191294)
13. Ichikawa W, Uetake H, Shirota Y, et al: Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Br J Cancer 89:1486-1492, 2003 (Pubitemid 37386604)
14. Metzger R, Danenberg K, Leichman CG, et al: High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with non-response to 5-fluorouracil. Clin Cancer Res 4:2371-2376, 1998 (Pubitemid 28477901)
15. Mizutani Y, Wada H, Yoshida O, et al: Significance of thymidine kinase activity in renal cell carcinoma. J Urol 169:706-709, 2003 (Pubitemid 36133027)
16. Pinedo HM, Peters GF: Fluorouracil: Biochemistry and pharmacology. J Clin Oncol 6:1653-1664, 1988
17. Salonga D, Danenberg KD, Johnson M, et al: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6:1322-1327, 2000 (Pubitemid 30226214)
18. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
19. Polak A, Eschenhof E, Fernex M, et al: Metabolic studies with 5-fluorocytosine-6-14C in mouse, rat, rabbit, dog and man. Chemotherapy 22:137-153, 1976
20. Wakisaka S, Shimauchi M, Kaji Y, et al: Acute phenytoin intoxication associated with the antineoplastic agent UFT. Fukuoka Igaku Zasshi 81:192-196, 1990 (Pubitemid 20197418)
21. Scarfe MA, Israel MK: Possible drug interaction between warfarin and combination of levamisole and fluorouracil. Ann Pharmacother 28:464-467, 1994 (Pubitemid 24123759)
22. Koyama Y: Japan Society for Cancer Therapy: Criteria for the evaluation of the clinical effects of solid cancer chemotherapy. J Jpn Soc Cancer Ther 28:101-130, 1993
23. The Japanese Urological Association: General Rules for Clinical and Pathological Studies on Renal Cell Carcinoma. Tokyo, Japan, Kanehara & Co Ltd, 1999
24. Motzer RJ, Mazumdar M, Bacik J, et al: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17:2530-2540, 1999 (Pubitemid 29368255)
25. Yagoda A, Abi-Rached B, Petrylak D: Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol 22:42-60, 1995
26. Petrioli R, Paolelli L, Francini E, et al: Capecitabine as third-line treatment in patients with metastatic renal cell carcinoma after failing immunotherapy. Anticancer Drugs 18:817-820, 2007 (Pubitemid 46975968)
27. Ellerhorst JA, Sella A, Amato RJ, et al: Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma. Cancer 80:2128-2132, 1997 (Pubitemid 27506026)
28. Negrier S, Caty A, Lesimple T, et al: Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil: Groupe Francais d'Immunotherapie, Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 18:4009-4015, 2000 (Pubitemid 32038392)
29. Kobayashi M, Ikeda H, Nukui A, et al: Clinical outcome and prognostic survival factors in patients with advanced renal cell carcinoma treated with very low-dose interleukin-2, interferon-alpha, and tegafururacil: A single-institution experience. Int J Clin Oncol 13:257-262, 2008 (Pubitemid 351871894)
30. Stadler WM, Halabi S, Rini B, et al: A phase II study of gemcitabine and capecitabine in metastatic renal cancer: A report of Cancer and Leukemia Group B protocol 90008. Cancer 107:1273-1279, 2006 (Pubitemid 44452776)
31. Tannir NM, Thall PF, Ng CS, et al: A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents. J Urol 180:867-872, 2008; discussion 180:872, 2008
32. Waters JS, Moss C, Pyle L, et al: Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma. Br J Cancer 91:1763-1768, 2004 (Pubitemid 39664962)
33. Soga N, Yamada Y, Nishikawa K, et al: Gemcitabine and capecitabine chemotherapy in Japanese patients with immunotherapy-resistant renal cell carcinoma. Int J Urol 16:576-579, 2009
34. Akaza H, Tsukamoto T, Murai M, et al: Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol 37:755-762, 2007 (Pubitemid 350120299)
35. Naito S, Yamamoto N, Takayama T, et al: Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: A cooperative group report of 1463 patients. Eur Urol 57:317-325, 2010
36. Jain RK: Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307:58-62, 2005
37. Motzer RJ, Michaelson MD, Redman BG, et al: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24:16-24, 2006 (Pubitemid 46630489)
38. Motzer RJ, Rini BI, Bukowski RM, et al: Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295:2516-2524, 2006 (Pubitemid 43854967)
39. Ichikawa W, Takahashi T, Suto K, et al: Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer. Br J Cancer 91:1245-1250, 2004 (Pubitemid 39424782)
40. Kamoshida S, Suzuki M, Shimomura R, et al: Immunostaining of thymidylate synthase and p53 for predicting chemoresistance to S-1/cisplatin in gastric cancer. Br J Cancer 96:277-283, 2007 (Pubitemid 46160633)
41. Takiuchi H, Kawabe S, Gotoh M, et al: Thymidylate synthase gene expression in primary tumors predicts activity of s-1-based chemotherapy for advanced gastric cancer. Gastrointest Cancer Res 1:171-176, 2007
42. Kirihara Y, Yamamoto W, Toge T, et al: Dihydropyrimidine dehydrogenase, multidrug resistance-associated protein, and thymidylate synthase gene expression levels can predict 5-fluorouracil resistance in human gastrointestinal cancer cells. Int J Oncol 14:551-556, 1999